Table 2 Time-independent parameters used in the model
From: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Point estimate | SE | Distribution | Ref. | |
|---|---|---|---|---|
Remission rates in responders | ||||
Usual care | 0.146 | 0.047 | Beta (α = 8.11; β = 47.34) | (10) |
5 mg/kg infliximab | 0.276 | 0.052 | Beta (α = 20.20; β = 52.95) | (10) |
10 mg/kg infliximab | 0.255 | 0.047 | Beta (α = 21.71; β = 63.44) | (10) |
Adalimumab | 0.276 | 0.052 | Beta (α = 20.20; β = 52.95) | |
Remission rates in non-responders | ||||
Usual care | 0.063 | 0.019 | Beta (α = 10.17; β = 152.17) | (10) |
10 mg/kg infliximab | 0.078 | 0.029 | Beta (α = 6.54; β = 76.96) | (10) |
Adalimumab | 0.100 | 0.020 | Beta (α = 22.40; β = 201.60) | (16) |
Probabilities | ||||
Early IPAA | 0.291 | 0.093 | Beta (α = 6.71; β = 16.29) | (8) |
Late IPAA | 0.087 | 0.010 | Beta (α = 66.99; β = 703.01) | (22) |
Early complications | 0.274 | 0.014 | Beta (α = 275.65; β = 728.83) | (23) |
Late complications | 0.507 | 0.016 | Beta (α = 527.02; β = 512.01) | (23) |
Successful treatment for complications | 0.840 | 0.031 | Beta (α = 117.60; β = 22.40) | (24) |
Costs (2008CA$) | ||||
Infliximab, 100 mg/vial | 952 | 50 | Gamma(α = 362.44; β = 2.63) | (25,26) |
Adalimumab, 400 mg | 715 | 46 | Gamma(α = 237.56; β = 2.98) | (25,26) |
Medical examination | 77 | (27) | ||
IPAA | 12,738 | 2548 | Gamma(α = 25.00; β = 509.52) | (28) |
Surgical complications | 9304 | 2301 | Gamma(α = 16.35; β = 569.08) | (28) |
Utilities | ||||
Remission | 0.79 | 0.035 | Beta (α = 108.43; β = 28.82) | (21) |
Active UC | 0.32 | 0.045 | Beta (α = 34.46; β = 73.23) | (21) |
Surgical remission | 0.68 | 0.042 | Beta (α = 83.77; β = 39.42) | (21) |
Surgical complications | 0.49 | 0.046 | Beta (α = 56.91; β = 59.23) | (21) |